Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: Ociperlimab|DRUG: Tislelizumab|DRUG: Paclitaxel|DRUG: Nab-paclitaxel|DRUG: Carboplatin|DRUG: Placebo|DRUG: Pembrolizumab|DRUG: Gemcitabine
Sponsor: Novartis Pharmaceuticals